News

Predictors of abnormal longitudinal patterns of lung-function growth and decline


 

References

When it comes to predictive demographic and clinical factors associated with abnormal patterns of lung growth and decline in those with persistent, mild-to-moderate asthma in childhood, male sex and childhood levels of lung function as assessed by the forced expiratory volume in 1 second (FEV1) make all the difference, according to the results of a study published in the New England Journal of Medicine.

“Determinants of abnormal patterns of FEV1 growth and decline are multifactorial and complex, and identification of factors associated with the timing of a decline from the maximal level requires longitudinal data,” said author Michael McGeachie, Ph.D., of Brigham and Women’s Hospital, Boston, and his colleagues.

©Sergey Nivens/thinkstockphotos

To identify these determinants, particularly in those with asthma, Dr. McGeachie and colleagues analyzed longitudinal data from a subset of participants from the Childhood Asthma Management Program (CAMP) cohort who were followed from enrollment at the age of 5 to 12 years, into the third decade of life. The trajectory of lung growth and the decline from maximum growth in this large cohort of persons who had persistent, mild-to-moderate asthma in childhood were compared against those from persons without asthma who were participants in the third National Health and Nutrition Examination Survey. (N Engl J Med. 2016;374:1842-52).

Data from 684 participants from the CAMP cohort were assessed and 25% had normal lung-function growth without an early decline, 26% had normal growth and an early decline, 23% had reduced growth without an early decline, and 26% had reduced growth and an early decline. Results of the multinomial logistic-regression analysis of risk factors for abnormal patterns of lung growth and decline showed that the 26% of participants with reduced growth and an early decline had lower FEV1 lung function at enrollment and were more likely to be male, compared with those who had normal growth.

Additional study results indicated that 18% of the participants who had reduced lung-function growth, with or without an early decline, met the case definition for chronic obstructive pulmonary disease (COPD) based on the postbronchodilator spirometric criteria at an age of less than 30 years.

Based on their data, Dr. McGeachie and his colleagues said that detection of an abnormal trajectory by means of early and ongoing serial FEV1 monitoring may help identify children and young adults at risk for abnormal lung-function growth that could lead to chronic airflow obstruction in adulthood.

Funding for this project was provided by grants from the Parker B. Francis Foundation, the National Institutes of Health, the National Human Genome Research Institute, and the Human Frontier Science Program Organization. Dr. McGeachie reported grant support from one of the funding sources during the conduct of the study. Nineteen coauthors reported they had nothing to disclose and the remainder either reported grant support or ties to industry sources.

Recommended Reading

PPIs caused remission in about half of esophageal eosinophilia cases
MDedge Internal Medicine
VIDEO: Treating your atopic dermatitis patients more effectively
MDedge Internal Medicine
ACIP recommends LAIV as an option for all people with egg allergies
MDedge Internal Medicine
AAAAI: Risks comparable in adult asthma patients given fluticasone and salmeterol plus fluticasone combo
MDedge Internal Medicine
First sublingual immunotherapy tablet for house dust mite allergic rhinitis may be U.S.-bound
MDedge Internal Medicine
Recently identified eczema comorbidities include anemia, obesity
MDedge Internal Medicine
Cochrane Review nixes specific allergen immunotherapy for atopic dermatitis
MDedge Internal Medicine
Sublingual immunotherapy for allergy-related asthma
MDedge Internal Medicine
Tiotropium inhalation spray effective for asthma regardless of allergic status
MDedge Internal Medicine
Novel device therapy shows continued benefits in pediatric peanut allergy
MDedge Internal Medicine